Cardinal Health (NYSE: CAH) has received an increased price target from multiple analysts, reflecting a positive outlook following the company’s latest earnings report. On January 15, 2024, Argus raised its price target from $211.00 to $232.00, maintaining a buy rating on the stock. Other analysts have also shown confidence in the company’s performance, indicating a strong consensus among financial experts.
Wells Fargo & Company recently adjusted their price target from $221.00 to $237.00, assigning an “overweight” rating to Cardinal Health. In addition, TD Cowen raised its target price from $183.00 to $225.00 with a buy rating, while Robert W. Baird set a target price of $250.00. Mizuho also provided an updated price target of $222.00. According to MarketBeat.com, the average rating for Cardinal Health’s stock is “Moderate Buy,” with a consensus target price of $221.07.
Cardinal Health’s strong financial performance contributed to these optimistic revisions. The company reported earnings per share of $2.55 for the quarter ending on October 30, 2023, surpassing analysts’ expectations of $2.22 by $0.33. The firm’s revenue reached $64.01 billion, exceeding the forecast of $59.41 billion. This marks a significant year-over-year revenue increase of 22.4%, up from $1.88 earnings per share in the same quarter the previous year.
Dividend Announcement and Institutional Investment
In addition to the positive earnings report, Cardinal Health declared a quarterly dividend of $0.5107, which was paid on January 15, 2024, to stockholders recorded on January 2, 2024. This results in an annualized dividend of $2.04, offering a dividend yield of 1.0%. The company’s payout ratio currently stands at 30.77%.
Institutional investors have also shown a keen interest in Cardinal Health. Redhawk Wealth Advisors Inc. increased its holdings by 0.5% in the fourth quarter, now owning 9,255 shares valued at $1.9 million. Similarly, HF Advisory Group LLC raised its stake by 0.9%, while Latitude Advisors LLC boosted its ownership by 2.1%. Overall, approximately 87.17% of Cardinal Health’s stock is held by institutional investors.
About Cardinal Health
Cardinal Health, headquartered in Dublin, Ohio, is a multinational healthcare services and products company. Established in the early 1970s, the firm has become a key player in providing supply chain and distribution services within the healthcare sector. Its core activities encompass the wholesale distribution of both branded and generic pharmaceuticals, as well as the supply of medical-surgical products and logistics solutions for hospitals, health systems, pharmacies, and clinical laboratories.
As Cardinal Health continues to enhance its market position, the recent upgrades from analysts and solid earnings performance highlight its resilience and potential for growth in the competitive healthcare landscape.
